Cargando…
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
BACKGROUND: Diarrheal diseases are a leading cause of global morbidity and mortality affecting all ages, but especially children under the age of five in resource-limited settings. Shigella is a leading contributor to diarrheal diseases caused by bacterial pathogens and is considered a significant a...
Autores principales: | Clarkson, Kristen A., Talaat, Kawsar R., Alaimo, Cristina, Martin, Patricia, Bourgeois, A. Louis, Dreyer, Anita, Porter, Chad K., Chakraborty, Subhra, Brubaker, Jessica, Elwood, Daniel, Frölich, Rahel, DeNearing, Barbara, Weerts, Hailey P., Feijoo, Brittany, Halpern, Jane, Sack, David, Riddle, Mark S., Fonck, Veronica Gambillara, Kaminski, Robert W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047506/ https://www.ncbi.nlm.nih.gov/pubmed/33813141 http://dx.doi.org/10.1016/j.ebiom.2021.103308 |
Ejemplares similares
-
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
por: Talaat, Kawsar R., et al.
Publicado: (2021) -
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
por: Riddle, Mark S., et al.
Publicado: (2016) -
Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei
por: Clarkson, Kristen A., et al.
Publicado: (2021) -
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score
por: Porter, Chad K., et al.
Publicado: (2018) -
The Ongoing Journey of a Shigella Bioconjugate Vaccine
por: Martin, Patricia, et al.
Publicado: (2022)